janssen science wordmark

Janssen COVID-19 Vaccine

(Ad26.COV2.S)

 

The Janssen COVID-19 Vaccine has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). The Janssen COVID-19 Vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA for active immunization to prevent Coronavirus Disease 2019 (COVID-19) in individuals 18 years of age and older for whom other FDA-authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and in individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the medical product under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act unless the declaration is terminated or authorization revoked sooner.

 

 

Vaccine Expiration Date

Expiration Date

 

Information on How to Obtain the Expiration Date on vaxcheck.jnj

Vaxcheck.jnj How-To Video

 

Report an Adverse Event

  • Report an Adverse Event to Janssen at 1-800-JANSSEN

Report a Product Quality Complaint

  • Report a Product Quality Complaint to Janssen at 1-800-JANSSEN 

Stability, Storage, and Dosing Administration

Centers for Disease Control & Prevention (CDC)

American Society of Hematology (ASH) Resources

Janssen Global Trial Finder

Clinical Trials

Phase 3

    COV3001 (ENSEMBLE)
    COV3009 (ENSEMBLE2)
   COV3012
   COV3021

Phase 2/3

   COV3006

Phase 2

   COV2001
   COV2004
   COV2008

Phase 1 / 2

   COV1001

Phase 1

   COV1002

Johnson & Johnson's Response to COVID-19

Additional Vaccine Safety Information

Additional Information About COVID-19 and COVID-19 Vaccines